HDL cholesterol: physiology, pathophysiology, and management

Area of Science:

• Cardiovascular Medicine
• Lipid Metabolism
• Pharmacology

Background:

• Epidemiological studies consistently identify high-density lipoprotein cholesterol (HDL) as an independent risk factor for coronary heart disease (CHD).
• HDL is recognized as a significant emerging therapeutic target for cardiovascular risk reduction, potentially comparable to statins.
• The anti-atherogenic effects of HDL are complex, influenced by metabolism, kinetics, subclasses, and genetic factors, which standard plasma measurements may not fully represent.

Purpose of the Study:

• To review the role of HDL cholesterol in cardiovascular disease.
• To explore HDL as a therapeutic target for coronary heart disease.
• To discuss current limitations and future directions in pharmacologic therapy for low HDL levels.

Main Methods:

• Literature review of epidemiological studies on HDL and CHD.
• Analysis of HDL metabolism, kinetics, and functionality.
• Evaluation of current and emerging pharmacologic therapies for HDL modulation.

Main Results:

• Low HDL levels are a significant risk factor for CHD.
• Existing therapies offer modest improvements in serum HDL levels.
• Emerging therapeutic strategies hold promise for more substantial impacts on HDL and CHD risk.

Conclusions:

• HDL cholesterol remains a critical target for cardiovascular disease prevention.
• Further research and clinical evidence are needed to establish formal HDL treatment guidelines.
• Novel pharmacologic interventions are anticipated to play a greater role in managing HDL levels and reducing CHD risk.